Pifeltro (Doravirine)

Brand Name

Pifeltro

Generic Name

Doravirine

View Brand Information

FDA approval date: July 20, 2018

Classification: Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor

Form: Tablet

What is Pifeltro (Doravirine)?

PIFELTRO ® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history; OR to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to doravirine. PIFELTRO, a non-nucleoside reverse transcriptase inhibitor , is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history, OR to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to doravirine.

Approved To Treat

HIV/AIDS

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Participants With HIV-1, Who Are 4 Weeks to Less Than 12 Years of Age and Weigh Less Than 45 kg

Who is this study for: Children aged 4 weeks to <12 years and weighing <45 kg who are infected with human immunodeficiency virus type 1

Enrollment Status: Recruiting

Publish Date: February 24, 2026

Intervention Type: Drug

Study Drugs: Doravirine, 2 NRTIs

Study Phase: Phase 2

Summary: This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 weeks to \<12 years and weighing \<45 kg, who are treatment-naive (TN) or have been virologically suppressed (VS) on stable combination antiretroviral therapy (cART) for ≥3 months with no history of treatment failure. The primary objectives are: * To eva...

Doravirine Dose Optimisation in Pregnancy

Enrollment Status: Recruiting

Publish Date: February 19, 2026

Intervention Type: Drug

Study Phase: Phase 4

Summary: A randomised, open label, controlled PK standard of care vs doravirine plus 2 nucleoside reverse transcriptase inhibitors backbone in pregnant women initiating combination antiretroviral therapy in the second trimester of pregnancy.

Phase III, Open-label, Randomized, Multicenter Trial EvaLuating the Non-inferiority of DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection

Enrollment Status: Recruiting

Publish Date: January 07, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: Phase III trial evaluating doravirine as an alternative to dolutegravir in treatment naïve people living with HIV-1 infection.

View All Clinical Trials